I-Mab (NASDAQ:NBP) Posts Earnings Results

I-Mab (NASDAQ:NBP) released its quarterly earnings results on Thursday. The company reported ($0.16) EPS for the quarter, FiscalAI reports.

I-Mab Price Performance

I-Mab stock opened at $2.00 on Friday. The firm has a market cap of $231.30 million, a PE ratio of -5.56 and a beta of 1.47. I-Mab has a 1-year low of $1.46 and a 1-year high of $6.79. The stock has a fifty day simple moving average of $1.78.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on NBP shares. Wall Street Zen raised I-Mab from a “sell” rating to a “hold” rating in a research report on Saturday. HC Wainwright reiterated a “buy” rating and issued a $9.00 target price on shares of I-Mab in a report on Thursday. Finally, Weiss Ratings raised shares of I-Mab from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, June 1st. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, I-Mab presently has an average rating of “Hold” and a consensus target price of $9.00.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in I-Mab stock. Brooklyn Investment Group purchased a new position in I-Mab (NASDAQ:NBP) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 12,715 shares of the company’s stock, valued at approximately $51,000. Hedge funds and other institutional investors own 38.38% of the company’s stock.

About I-Mab

I-Mab is a clinical-stage biotechnology company focused on the discovery, development and commercialization of biologic therapies for oncology and immunology indications. The company concentrates on advancing antibody-based therapeutics and other protein biologics intended to modulate the immune system to treat cancer and autoimmune or inflammatory diseases. Its development activities span preclinical research through late-stage clinical trials, with an emphasis on creating targeted, differentiated molecules designed to address unmet medical needs.

Headquartered in China with global development activities, I-Mab operates research and development facilities and engages with clinical investigators and regulatory authorities across multiple geographies to support global clinical programs.